Navigation Links
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Date:8/27/2008

- First Phase 3 data, from BLISS-52 trial, expected by mid-2009 -

- Data from second Phase 3 trial, BLISS-76, expected by fall 2009 -

ROCKVILLE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B(R) (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"If LymphoStat-B is successful in Phase 3, we believe that it could represent a breakthrough in the treatment of patients suffering from SLE," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We have now completed enrollment in both of our LymphoStat-B Phase 3 trials. We are on track to have data from our first Phase 3 trial by mid-2009, and data from our second Phase 3 trial by fall 2009. Assuming positive results, we anticipate a BLA filing in the United States in the first half of 2010."

BLISS-76 was initiated in February 2007, and has enrolled and randomized 826 patients at 133 clinical sites in 19 countries, primarily in North America and Europe. In April 2008, BLISS-52, the first of the two belimumab Phase 3 trials, completed the enrollment of 867 patients at 90 clinical sites in 13 countries, primarily in Asia, South America and Eastern Europe.

"The BLISS studies are the largest double-blinded clinical trials ever conducted in lupus," said J
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...re-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),acli...ing,developingandcommercializingnoveldrugstotreatv...lyearendedSeptember30,2009.AtSeptember30,2009Pharm...tterminvestments. ,, PipelineUpdateand2009High..., InlateNovember2009,anindependentDataMonitoringCo...
(Date:11/25/2009)...wswire-FirstCall/--Formanyofthemillionsofhearingim...treated hearingloss ,theholidaysmaynotbeallthathap...rvicepresidentofHearUSA(Amex: EAR ),oneofAmerica,s...udieshavelinkedhearinglosstostress,frustration,and...daygatheringswithfamiliesandfriends,whenmanyofthos...
(Date:11/25/2009)...portlinker.comannouncesthatanewmarketresearchrepor...talDevicesMarketAnalysisandForecaststo2015 ,, ...s-Dental-Devices-Market-Analysis-and-Forecasts-to-...alysisandForecaststo2015 ,, Summary ,, Thi...ddatarelatingtotheUSdentaldevicesmarket.Italsooffe...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 48650 1Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 48650 2Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 48650 3Partnership for Prescription Assistance Prepared to Help Wyoming Workers Hurt by Recession 48650 4New American College of Surgeons risk calculator determines colorectal surgery risk 48647 1New American College of Surgeons risk calculator determines colorectal surgery risk 48647 2New American College of Surgeons risk calculator determines colorectal surgery risk 48647 3Brown 26 Toland Announces 2008 Financial Results 48645 1Brown 26 Toland Announces 2008 Financial Results 48645 2
...Multicenter Trial Will Test Ability of Adecatumuma...tients with Liver Metastases , , BETHESDA, Md., M...pharmaceutical company developing novel, proprieta...ation and autoimmune diseases, today announced the...trial of its human anti-EpCAM IgG1 antibody adecat...
...Innocoll, Inc., a privately-held biopharmaceutical... dosed in the second of two ongoing U.S. phase 3 c...diary, Innocoll Technologies Ltd, to investigate C...ention of surgical site infections. , , The trial...ites across the U.S. and has enrolled 600 patients...
Other Medicine Technology:Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 2Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 3Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 4Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 5Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients 2Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients 3
(Date:11/26/2009)...r too heavy can lead to strains or worse , ...ay be nothing wrong with stuffing your turkey full...e thing with your suitcase as you pack for holiday...in 2008 in U.S. hospital emergency rooms, doctors,... luggage-related injuries, such as muscle strains,...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Center, a p...is one of a growing number of physicians who are ...s to connect with individuals who are interested i...besity. Dr. Kim is utilizing Facebook to share bef...ctice with the community. , ...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free nationw...d Yasmin birth control pills who have suffered a D...oke, Heart Attack or other related cardiac issues ...oll free at 1-800-856-6405 or go to the firm&rsquo...ut an online case evaluation form. , ...
(Date:11/25/2009)....,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceutic...ywillhosttwoinvestoreventsinDecember: ,, ASHB....m.ET ,, Principalinvestigatorswilldiscussdat...orrefractorymultiplemyeloma,asfeaturedatthe51stAme...itioninNewOrleans,LA.Theteleconferencewillbeginat9...
(Date:11/25/2009)...,Nov.25/PRNewswire/--Thanksgivingmealswillbedelive...rLongBeachareathankstoFaithInAction/VolunteerActio...),adivisionofSCANHealthPlan.Formorethan17yearsthes...liverwarmThanksgivingmealstoseniorsinneedinLongBea...surroundingcities. ,, "Ourwarmholidaymealsarede...
Breaking Medicine News(10 mins):Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2
...ing to a village in Bihar was left for herself to ...IDS, as nobody turned up// give a helping hand. Th...t and performed his last rites herself. Grief-s... to console her. A mother of three, she told d...
...een accorded a further six months of patent extens...eatment medication//, Provigil. Cephlaon ha...equest that entailed the provision of clinical stu...our generic firms, and under this settlement, each...
... Manmohan Singh has announced the set-up of a publ...he imbalances in the provision of health care serv...ate initiative that will redress the inequalities ...ion of India will endeavor to institute five world...
...o had dismissed increased risk of heart attack ass...o argue that his views are 'out of the mainstream'...he drug company, Merck and Co. Thomas Cona a... has been filed against the controversial Vioxx, o...
...ers , who carry a high risk of the potentially-fa...hey do not consume large doses of Vitamin C and E...n large doses are not beneficial to pregnant women...s a common cause of deaths and still born babies. ...
... Minister Tony Clement assured patients frustrated... their health care providers to the court for not ...can open the door to legal action if the promise w...is essential. Clement said this while, speaking at...
Other Medicine News:Health News:Doctor Grilled In Court For False Report About Vioxx Health Risk 2